Samlyn Capital, LLC Reata Pharmaceuticals Inc Transaction History

Samlyn Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$100.0 - $143.02 $7.87 Million - $11.3 Million	-78,672 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$78.27 - $151.29 $6.16 Million - $11.9 Million	78,672 New	78,672 $11.1 Million
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $8.53 Million - $17 Million	-68,699 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $203,203 - $593,832	2,725 Added 4.13%	68,699 $14 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $4.7 Million - $6.32 Million	65,974 New	65,974 $5.3 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samlyn Capital, LLC with notifications on news.